Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX)
A biopharmaceutical company building an oncology business by developing and commercializing innovative therapies that target the molecular mechanisms implicated in cancer.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
zzlangerhans
(99.78)
Submitted: 5/11/2013 2:00:44 PM :
Start Price:
$89.90
ONXX Score:
+3.84
Since the approval of Kyprolis last year, Onyx has become a solid mid-cap stock and one of the biopharma "blue chips". The transformation from a predominantly developmental company to a drug marketer has made me less comfortable predicting the direction of the share price in the short term, but Portefeuille seems to like the way these stocks reflect the overall upward trend in the sector. At his suggestion, I bought 80 shares at 93.14 on May 3 for our collaboration. To follow our trades in real-time on Twitter, follow us @zzlangerhans and @portefeuillefun or search the hashtag #zzporte.
Recs
justaboutperfect
(< 20)
Submitted: 4/12/2013 9:41:04 AM :
Start Price:
$97.24
ONXX Score:
+6.05
Trying to catch a shooting star before it fall from FDA red thumb
Recs
CarlosDK
(62.75)
Submitted: 1/21/2013 8:00:23 PM :
Start Price:
$76.77
ONXX Score:
-12.60
High value in all fin stockscreener
Recs
IBDContrarian
(< 20)
Submitted: 12/18/2012 10:52:24 AM :
Start Price:
$79.57
ONXX Score:
-5.45
IBD EPS, RS, SPROE, Acc ratings plus P/E and div yield
MEDICAL 1 97 CB, NO EARNINGS
Recs
SnarkyApple
(61.44)
Submitted: 9/27/2012 4:19:42 PM :
Start Price:
$84.50
ONXX Score:
+2.03
Shenanigans.
Recs
NHWeston102
(76.49)
Submitted: 7/31/2012 8:20:34 PM :
Start Price:
$74.37
ONXX Score:
+8.87
Steady revenue growth and a [temporarily] slipping price that offers a buying opportunity.
Recs
BillZack
(< 20)
Submitted: 6/26/2012 3:41:16 PM :
Start Price:
$67.42
ONXX Score:
-16.26
Nice pop, but getting ahead of itself. Extended on any technical chart you want to analyze.
Recs
7ayyan
(< 20)
Submitted: 4/17/2012 9:35:21 PM :
Start Price:
$41.12
ONXX Score:
+112.20
Many promising drugs in pipeline
Recs
docmase
(32.88)
Submitted: 11/5/2011 11:26:14 PM :
Start Price:
$39.68
ONXX Score:
+108.16
Onyx has scored a major victory against Bayer in getting rights to regorafenib. Carfilzomib looks great.
Recs
PharmaD
(92.37)
Submitted: 10/26/2011 11:22:49 PM :
Start Price:
$40.29
ONXX Score:
+106.84
Strong pipeline
Recs
EclecticRecluse
(77.84)
Submitted: 5/5/2011 4:31:17 AM :
Start Price:
$36.88
ONXX Score:
-134.93
Earnings Estimates Revised Downward
Recs
recipe1939
(< 20)
Submitted: 4/20/2010 1:12:04 AM :
Start Price:
$29.66
ONXX Score:
+183.96
developement of sucessful drug
Recs
jdm1234567892002
(< 20)
Submitted: 3/26/2010 3:34:38 PM :
Start Price:
$30.92
ONXX Score:
+166.19
Based on hopes of further approvals in 2010.
Recs
Recs
mizims
(21.66)
Submitted: 10/27/2009 2:36:05 AM :
Start Price:
$25.26
ONXX Score:
+222.55
my be a bore in the short term, but long term it will be a winner
Recs
HIGHG33K
(73.65)
Submitted: 10/21/2009 3:58:19 PM :
Start Price:
$25.17
ONXX Score:
+225.61
Well undervalue mid-sized biotech with a buyout potential over $50 and possible positive clinical results in 2 years.
Recs
GravityGun
(< 20)
Submitted: 8/3/2009 11:40:31 AM :
Start Price:
$36.00
ONXX Score:
+98.53
I think people will use this drug for alternative cancer treatments before approved by the FDA. It's already greenlighted in many countries abroad.
Recs
jjam79095
(72.54)
Submitted: 7/27/2009 11:49:36 AM :
Start Price:
$35.16
ONXX Score:
-100.94
Good market but stale growth right now.
Recs
euphorbus
(53.50)
Submitted: 6/3/2009 10:20:16 PM :
Start Price:
$25.26
ONXX Score:
+199.30
Onyx will get bought out within two years.
Recs
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 73 : 1 2 3 4 Next »